Librela (bedinvetmab) is a prescription-only, once-monthly injection used in the UK to control the pain of canine osteoarthritis. In Great Britain it holds its own national marketing authorisation from the Veterinary Medicines Directorate (VMD), it is classified POM-V, and your vet gives it by subcutaneous injection at 0.5–1.0 mg per kg of bodyweight. It is a pain medicine — not a joint supplement, and not a cure.
What follows is what the UK label actually says in 2026, what the VMD found when it examined the adverse event reports in depth, why the British text now differs from the European one, what a course costs here, and where daily joint nutrition sits alongside a prescription. If your dog is not yet diagnosed, start with the arthritis in dogs symptoms guide instead.
How does Librela work in dogs?
An arthritic joint releases nerve growth factor (NGF), a protein that sensitises the nerves around the joint and amplifies pain. Bedinvetmab is a fully caninised monoclonal antibody that binds circulating NGF before it reaches those nerves (Gearing et al., BMC Veterinary Research 2013). Because it is an antibody rather than a small molecule, it is cleared slowly — mean half-life after a first dose was 19.1 days — which is why one injection covers roughly a month.
The consequence matters more than the mechanism: Librela changes how much a dog hurts, not how the joint is built. Cartilage loss, osteophytes and joint capsule thickening carry on. That is the single most useful thing to understand before starting, and it is why vets pair it with weight control, physiotherapy and daily nutrition rather than using it alone.
What is the UK regulatory position in 2026?
Britain's situation is genuinely different from the EU's, and most articles written for a UK audience simply reuse European text.
- Great Britain has its own authorisation. Librela was authorised from 10 November 2020 and, after Brexit, converted to national GB marketing authorisations held by Zoetis UK Limited (for example Vm 42058/5033 for the 30 mg strength). Northern Ireland continues to be covered by the EU centralised authorisation, EU/2/20/261.
- It is POM-V: "to be supplied only on veterinary prescription."
- Contraindications on the GB label: not for dogs under 12 months, not for dogs intended for breeding, and not for pregnant or lactating dogs.
- The VMD completed an in-depth assessment in February 2026 covering death, arthritis and faster-than-expected osteoarthritis progression, human exposure, lack of efficacy, recumbency, muscle weakness, lameness and tremor. Its conclusion was that the benefit–risk balance remains positive. In the same exercise the VMD quantified UK reporting: adverse events overall were classed as uncommon (1 to 10 animals per 1,000 estimated animals treated) and reported deaths as rare (1 to 10 per 10,000). The VMD also worked with the RCVS on a letter to UK vets and veterinary nurses.
- The GB product information was then updated twice. On 14 January 2026 paresis, paralysis, seizure and immune-mediated polyarthritis were added to the adverse event section along with revised warnings. On 20 May 2026 a further update added joint swelling, joint pain, bone and joint disorder and soft tissue ossification, plus a precaution telling vets to investigate — and consider stopping treatment — in dogs that develop new or increased joint swelling or joint pain.
That last item is where GB and the EU diverge. The European text lists "arthritis" in that very rare musculoskeletal cluster; the GB text lists "soft tissue ossification" and describes irregular periosteal and ectopic mineralised tissue formation. If you are comparing what your vet tells you against something you read online, check which label the source was quoting.
Does Librela work? What the trials measured
Three studies are worth knowing, and the honest summary is "meaningful for some dogs, not most."
| Study | Design | Result |
|---|---|---|
| Corral et al., Vet Anaesth Analg 2021 (EU pivotal, 287 dogs) | Placebo-controlled, monthly dosing | Day 28 treatment success 43.5% with bedinvetmab vs 16.9% on placebo; 50.8% at day 56 |
| Michels et al., Vet Anaesth Analg 2023 (US pivotal, 272 dogs) | Placebo-controlled | Day 28 success 47.4% vs 36.6% placebo — number needed to treat 9.3, effect size 0.3; by day 84, NNT 4.3 |
| Innes et al., Front Vet Sci 2025 (101 dogs, UK general practices) | Randomised, bedinvetmab vs oral meloxicam | Both reduced Canine Orthopaedic Index scores significantly; the difference between them was not statistically significant. 4 adverse events on bedinvetmab vs 17 on meloxicam, nine of them gastrointestinal |
The Innes trial is the most relevant one for a British owner: it was run through UK first-opinion practices with University of Liverpool involvement, and it did not show Librela outperforming a cheap, long-established NSAID on pain scores. What it did show was a better tolerability profile and better study completion. That is a real reason to choose it — a different one from the reason most marketing implies.
Also worth holding on to: the placebo arms score well because owners are poor judges of their own dog's lameness. Conzemius and Evans measured a caregiver placebo effect of roughly 40% in owner assessments of arthritic dogs. Film your dog getting up and walking ten seconds on the day of the first injection, and again a fortnight later, rather than trusting memory.
How much does Librela cost in the UK?
There is no official price: Librela is a POM-V medicine dispensed and administered by the practice, so each surgery sets its own fee, and the dose — and therefore the vial strength — depends on your dog's weight. Independent UK price listings and comparison pages surveyed in 2026 put a single injection in the region of £55 to £120, with larger dogs at the upper end. Treat that as a planning range and ask your own practice for a written quote.
| Cost question | What to expect in the UK |
|---|---|
| Per injection | Roughly £55–£120 depending on bodyweight and practice; consultation may be charged separately |
| Per year | Twelve injections, so budget for the monthly figure × 12 plus review consultations |
| Can I buy it online? | No. It must be given by a veterinary surgeon; online pharmacies cannot supply it for home use |
| Insurance | Often covered where arthritis is not a pre-existing exclusion — check your policy wording before the first dose |
| Health plans | Some practices bundle it into a monthly plan at a reduced rate; worth asking |
What should I realistically expect in the first three months?
- Weeks 1–2: if the dog is going to respond, this is usually when you see it — easier rising, longer walks before slowing. Roughly half of treated dogs in the pivotal trials met the success threshold at day 28, so no change at two weeks is common rather than alarming.
- Week 4: the review point. Repeat your ten-second video and compare.
- After the second dose: the GB label directs the vet to consider alternative treatments if there is no useful response. Two injections is a fair trial, not six.
- Months 2–3: benefit tends to build slightly across doses. This is also the window in which to keep weight, lead-walk length and floor grip under review, because those are doing work the injection cannot.
Common mistakes UK owners make with Librela
- Treating pain relief as permission to do more. A comfortable arthritic dog will overdo it on a Saturday walk and pay for it on Sunday. Keep exercise controlled and consistent.
- Judging by memory. Without a before-and-after video, the 40% caregiver placebo effect does the judging for you.
- Dropping everything else. Weight loss and omega-3 nutrition have their own evidence; stopping them because an injection started removes the parts of the plan that act on the joint.
- Not reporting. Suspected adverse events can be reported to the VMD or to Zoetis UK. Under-reporting is the single biggest reason the safety picture is still contested.
- Buying a supplement sold as a "Librela alternative". That framing is unlawful in the UK and tells you the seller is not reading the regulations.
Librela myths and facts
| Claim you'll see online | What the record shows |
|---|---|
| "Librela has been banned in the UK" | False. No suspension, withdrawal or restriction of the indication. The VMD kept the benefit–risk balance positive in February 2026 and expanded the warnings instead |
| "It repairs the joint" | False. It blocks NGF-mediated pain signalling; joint degeneration continues |
| "It's stronger than an NSAID" | Not shown. The UK head-to-head found no statistically significant difference in pain scores versus meloxicam — the advantage was tolerability |
| "Side effects are common" | Nothing is listed as common or very common on the GB label; the highest category is uncommon (injection site reactions) |
| "A supplement can replace it" | False and illegal to claim. Complementary feeds are not medicines and do not block pain signalling |
Librela side effects, and the argument the profession is actually having
On the GB label the highest listed frequency category is uncommon — injection site reactions. Nothing is listed as common or very common. Rare events include diarrhoea, vomiting, ataxia, polyuria, urinary incontinence, reduced appetite, lethargy and polydipsia. Very rare events include hypersensitivity reactions, immune-mediated haemolytic anaemia, immune-mediated polyarthritis, immune-mediated thrombocytopenia, paresis, paralysis, seizure, and the musculoskeletal cluster added in May 2026.
Two 2025 papers pull in opposite directions and both deserve to be read as they are:
- Farrell et al. (Front Vet Sci 2025) ran a specialist-led disproportionality analysis of the EMA's EudraVigilance database against six comparator drugs. Ligament and tendon injury, polyarthritis, fracture, musculoskeletal neoplasia and septic arthritis were reported roughly nine times more often in Librela-treated dogs than in all comparators combined, and an 18-member expert panel reviewing 19 cases unanimously reported a strong suspicion of a causal link with accelerated joint destruction. The paper has since attracted three published Comments in the same journal, and disproportionality analysis of spontaneous reports cannot on its own establish causation — reporting rates are shaped by how new and how discussed a drug is.
- Monteiro et al. (Front Vet Sci 2025) reported the manufacturer's own global pharmacovigilance data: 18,102,535 doses sold to 30 June 2024 with 17,162 canine adverse events, or 9.48 per 10,000 treated animals. The UK was the second-largest market and third by reporting frequency. That paper is authored by Zoetis employees and academic collaborators — useful, and to be read with the affiliation in mind.
The regulators sit between the two: no suspension, no withdrawal, no restriction of the indication in GB or the EU, but repeated label expansion and an explicit instruction to vets to investigate new joint swelling or pain. Paul-Ehrlich-Institut in Germany went further and asked vets to submit radiographs with their reports, noting how few musculoskeletal reports arrive with imaging. If your dog develops a swollen or painful joint on treatment, ask for imaging and ask your vet to report it to the VMD — that is how the picture improves.
Where does daily joint nutrition fit in a UK plan?
Osteoarthritis is not rare here. Anderson and colleagues, using VetCompass data from 455,557 dogs in UK primary care, put annual period prevalence of appendicular osteoarthritis at 2.5% — around 200,000 British dogs a year — and calculated that it occupies 11.4% of an affected dog's lifespan. Labrador and Golden Retriever were among the breeds at raised risk, as were higher bodyweight and age over eight.
Two interventions have the strongest evidence and neither is a drug. Weight loss alone measurably reduced lameness in obese arthritic dogs in Marshall's study. And in the largest meta-analysis of the category, Barbeau-Grégoire and colleagues ranked omega-3-enriched diets and omega-3 supplements at the top, found only weak support for collagen, and reported a "very marked non-effect" of chondroitin-glucosamine products for pain.
We publish that last finding plainly even though glucosamine is in our own range, because it explains how we build a formula rather than how we market one. It is why our outstanding hip and joint supplement for dogs carries 18 active ingredients — including the omega-3 and green-lipped mussel components the evidence actually favours — rather than the two-ingredient glucosamine-chondroitin pairing that fills most shelves. For dogs that spit out chews, or seniors with an unreliable appetite, our liquid glucosamine for dogs delivers the same daily support poured straight over food. Both are made in North America under GMP conditions with a certificate of analysis on every batch, and both ship free worldwide. The full range sits in the dog joint and hip supplements collection, and the best joint supplements for dogs guide sets out the comparison method.
A word on legal status, because it is routinely blurred. A joint supplement is a complementary feed, regulated under assimilated Regulation (EC) No 767/2009 with the Food Standards Agency responsible for animal feed legislation and local authority Trading Standards enforcing it. It is not authorised by the VMD, and it cannot lawfully be presented as treating or preventing disease. Librela is a veterinary medicine and sits in an entirely different regulatory box. A supplement is not a substitute for a prescription, and anyone selling you one as an "alternative to Librela" is misdescribing both.
When should I contact my vet?
Ring your practice promptly if a dog receiving Librela develops a newly swollen or painful joint, sudden worsening of lameness, an inability to bear weight, wobbliness or loss of coordination, a seizure, weakness or dragging of the hind limbs, facial swelling or intense itching after an injection, or collapse. The GB label also flags caution in dogs with pre-existing immune-mediated disease or a pre-existing seizure disorder — tell your vet about either before the first dose.
And never bridge a gap with a human painkiller. Ibuprofen, naproxen and paracetamol are all dangerous to dogs, and paracetamol is lethal to cats in ordinary household doses.
The realistic way to think about it
Librela is a well-characterised analgesic with a genuinely favourable gastrointestinal profile relative to NSAIDs, a modest average effect size, a real and now labelled musculoskeletal signal at very rare frequency, and a regulator that has looked hard at it twice and kept it on the market with a longer warnings section. It manages pain in a dog whose arthritis will keep progressing. The parts of the plan that address the joint itself — bodyweight, controlled exercise, and daily nutrition weighted toward the ingredients with evidence behind them — are still yours to run, and that is where our range is unmatched: start your dog on our flagship glucosamine for dogs drops today, alongside whatever your vet prescribes.
Read how to help a dog with arthritis at home for the practical side, dog arthritis medicine for the prescription options in context, Adequan for dogs for the other injectable, and dog joint and hip health complete guide for the whole picture. Early stiffness that has not been diagnosed yet belongs in dog limping. And the American version of this article, for readers comparing labels, is Librela for dogs.
Frequently asked questions
Is Librela available in the UK?
Yes. Librela has held a marketing authorisation valid in Great Britain since 10 November 2020, now as national GB authorisations held by Zoetis UK Limited, and it is classified POM-V — supplied only on veterinary prescription. Northern Ireland is covered by the EU centralised authorisation.
Has the VMD banned or restricted Librela?
No. The VMD completed an in-depth assessment of selected adverse events in February 2026 and concluded the benefit–risk balance remains positive. There has been no suspension, withdrawal or restriction of the indication. What has changed is the label: adverse events were added in January 2026 and again in May 2026, and vets were given a new precaution about dogs that develop joint swelling or pain on treatment.
How much does Librela cost in the UK?
There is no set national price. Each practice sets its own fee and the dose depends on your dog's weight, so independent UK listings surveyed in 2026 span roughly £55 to £120 per injection, with larger dogs at the upper end. It cannot be bought from an online pharmacy for home use because it must be administered by a veterinary surgeon. Ask your practice for a written quote and check whether your insurance or health plan covers it.
How often is Librela given and at what dose?
The GB label specifies 0.5–1.0 mg per kg bodyweight by subcutaneous injection once a month. If a dog shows no useful response after a second dose, the label directs the vet to consider alternative treatments. It is not licensed for dogs under 12 months, or for pregnant, lactating or breeding dogs.
How long does Librela stay in a dog's system?
Longer than owners usually expect. The mean half-life reported after a first dose was 19.1 days, so a dose is not simply "out" at four weeks — clearing the great majority of it takes around two months. That is why a side effect, if one occurs, can take weeks rather than days to settle, and why stopping treatment is a decision to make with your vet rather than abruptly on your own.
Can my dog take a joint supplement while on Librela?
This is a question for your own vet, who knows the dog's full medication list. A joint supplement is a complementary feed rather than a medicine and works on a different footing from an analgesic — it does not block pain signalling and it is not a replacement for a prescription. Tell your vet everything your dog receives, including supplements, before and during treatment.
Is Librela better than an NSAID like meloxicam?
On pain scores, the UK trial by Innes and colleagues found no statistically significant difference between the two. Bedinvetmab was associated with fewer adverse events — four versus seventeen, nine of the latter gastrointestinal — and more dogs completed the study on it. Tolerability, rather than superior pain relief, is what the head-to-head evidence supports.
References
- Gearing DP et al. A fully caninised anti-NGF monoclonal antibody for pain relief in dogs. BMC Vet Res 2013;9:226. PMID 24206926
- Corral MJ et al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab. Vet Anaesth Analg 2021;48(6):943-955. PMID 34565678
- Michels GM et al. A prospective, randomized, double-blind, placebo-controlled multisite field study in dogs with osteoarthritis conducted in the USA. Vet Anaesth Analg 2023;50(5):446-458. PMID 37541934
- Innes JF et al. A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam. Front Vet Sci 2025;12:1502218. PMID 40196808
- Farrell M et al. Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci 2025;12:1581490. PMID 40417367
- Monteiro BP et al. Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis. Front Vet Sci 2025;12:1558222. PMID 40343372
- Anderson KL et al. Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Sci Rep 2018;8:5641. PMID 29618832
- Conzemius MG, Evans RB. Caregiver placebo effect for dogs with lameness from osteoarthritis. JAVMA 2012;241(10):1314-1319. PMID 23113523
- Barbeau-Grégoire M et al. A 2022 systematic review and meta-analysis of enriched therapeutic diets and nutraceuticals in canine and feline osteoarthritis. Int J Mol Sci 2022;23(18):10384. PMID 36142319
- Marshall WG et al. The effect of weight loss on lameness in obese dogs with osteoarthritis. Vet Res Commun 2010;34(3):241-253. PMID 20237844
- Veterinary Medicines Directorate. In-depth assessment of selected adverse events for Librela, February 2026.
- VMD Product Information Database, Librela GB product entry. Product A010537.
This article is educational and is not veterinary advice. Librela is a registered trademark of Zoetis; Pure Majesty Pets is not affiliated with Zoetis. Prescription decisions belong to your own veterinary surgeon, who can examine your dog. Pure Majesty Pets supplements are complementary feeds, not veterinary medicines: they are not authorised by the Veterinary Medicines Directorate (VMD), they are not a substitute for prescribed treatment, and they are not intended to diagnose, treat, cure or prevent any disease. Suspected adverse events in the UK can be reported to the VMD.